Germany-based BASF, the world’s largest chemical company, is introducing Hepaxa, a product that can help tens of millions of patients manage non- alcoholic fatty liver disease (NAFLD), one of the most common forms of chronic liver disease. 22 February 2018
Japan’s Santen Pharmaceutical has reshuffled its executive team, appointing current senior corporate officer Shigeo Taniuchi as president and chief operating officer. 22 February 2018
Cardiovascular disease, which includes heart disease and stroke, is the leading cause of death in the USA, accounting for one out of every three deaths, according to a web posting 22 February 2018
Hikma Pharmaceuticals has appointed Sigurdur Olafsson as chief executive, with immediate effect. Current CEO and chairman Said Darwazah will become executive chairman. 20 February 2018
Pharma services firm Clinigen Group has initiated an Expanded Access Program (EAP) in the USA with Switzerland-based Santhera Pharmaceuticals for idebenone in patients with Duchenne muscular dystrophy (DMD) who are in respiratory decline. 20 February 2018
Both ALK-Abelló and Stallergenes Greer were able to announce Japanese approval of pediatric use for their house dust mite allergy treatments on Friday. 16 February 2018
Another instance of massive price gouging in the US pharma market has been revealed by the Financial Times, this time by Ireland-based Horizon Pharma, regarding its arthritis drug Vimovo (naproxen/esomeprazole magnesium), which combines a painkiller with an antacid ingredient. 16 February 2018
Japan’s Sumitomo Dainippon has handed back to Intercept Pharmaceuticals the rights to develop and commercialize DSP-1747 (obeticholic acid), also known as OCA, in Japan and South Korea. 16 February 2018
Switzerland’s Novartis has received $6.5 million from the Bill & Melinda Gates Foundation to develop cryptosporidiosis candidate KDU731. 14 February 2018
South Korea’s GC Pharma (formerly known as Green Cross Corp) and Lee's Pharmaceutical (HK) Limited have entered into an agreement granting Lee's Pharm exclusive rights to develop and commercialize GCC-4401C. 14 February 2018
AIM-listed Diurnal has been granted a paediatric use marketing authorisation (PUMA) in Europe for Alkindi as replacement therapy of adrenal insufficiency (AI) in infants, children and adolescents. 13 February 2018
Medtech pioneer Proteomics International has entered into a strategic alliance with fellow Australia-based CPR Pharma Services (CPR), targeting the high growth area of clinical trials and related research, with an offer to acquire 10% of CPR's share capital through the issue of 4 million PIQ shares. 12 February 2018
Adding to US approval last December, Novo Nordisk today announced that the European Commission (EC) has granted marketing authorization for Ozempic (semaglutide) for the treatment of adults with type 2 diabetes. 9 February 2018
The stopgap budget deal wending its way through the US Congress will include $6 billion to help address the opioid addiction crisis, according to The Hill. 8 February 2018
Los Gatos, California-based Xoc Pharmaceuticals has secured $30 million in series A funding to develop central nervous system (CNS) therapies. 8 February 2018
Japan’s Astellas Pharma says two Phase III trials - RAJ3 and RAJ4 - of ASP015K (peficitinib hydrobromide) in rheumatoid arthritis met their primary endpoints. 8 February 2018
UK cannabinoid drug specialist GW Pharmaceuticals says that the European Medicines Agency has accepted for review its Marketing Authorization Application (MAA) for Epidiolex (cannabidiol) for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome. 6 February 2018
German pharma and crop sciences major Bayer has offered concessions to allay European Union antitrust concerns about its $63.5 billion bid for US agri-chemical and seed rival Monsanto announced in September 2016, according to the European Commission, extending its investigation of the deal to April 5, according to a Reuters report. 5 February 2018
London-listed Faron Pharmaceuticals has agreed terms for German CRO Lyocontract to manufacture Traumakine, for the treatment of acute respiratory distress syndrome. 5 February 2018
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024